Aardvark Pharma (AARD) Cash per Single Share

Aardvark Pharma - graphic logo of issuer AARD

Aardvark Therapeutics Inc (AARD) is developing ARD-101, an oral obesity drug that works by activating TAS2R receptors. Strict FDA oversight and patent protection shield their developments from competition. Stable demand for weight loss transforms this platform into a reliable cash cow. An analysis of cash per share helps assess liquidity, where 2.74 determines the current value of the metric on the chart.

Aardvark Therapeutics (AARD): Cash per Share from 02/14/2025 to 11/21/2026

Comprehensive metric breakdowns and analytics for Aardvark Therapeutics Corp (AARD)

- market value and analyst target forecast:
- cash availability and cash flow indicators:
General company analysis:Aardvark Therapeutics Corp
Flagship merchandise of Aardvark Therapeutics Inc.

Developing obesity drugs requires significant clinical trial expenditures, making the financial autonomy of Aardvark Therapeutics Inc (AARD) critically important. By analyzing cash per share via GURU.Markets, an investor can see the proportion of liquid reserves in each share, allowing for an assessment of the company's ability to fund R&D without equity dilution while avoiding the inefficient freezing of excess funds.